Very encouraging results, albeit very small scale safety trial - but if replicated in a larger trial would be very positive.
I do note that the median age for the treated group is about double that in the control group (17.9 months vs 9.0 months). Potential confounder - I would expect older babies with a larger heart would more likely to progress to complete BiV.
Notwithstanding that, the 3-D echocardiographic LVEDV data (indexed to body surface area) are impressive, especially at the 3 week mark (an effect not seen though in the MRI analysis).
Some interesting and perhaps confusing stuff as you drill down in the data, highlighting the need identified by the authors for more trials. I'm sure the data from this study will assist in designing a larger trial.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Grants Rare Pediatric Disease Designation for Revascor
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-154
-
-
- There are more pages in this discussion • 227 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 94863 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 5000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85863 | 1.125 |
3 | 60500 | 1.120 |
3 | 49858 | 1.115 |
10 | 234700 | 1.110 |
3 | 20500 | 1.105 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 1000 | 1 |
1.135 | 15000 | 2 |
1.140 | 10000 | 1 |
1.150 | 27892 | 3 |
1.155 | 25000 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |